CSIMarket
 
Instil Bio Inc   (TIL)
Other Ticker:  
 
 
Price: $12.4100 $-0.06 -0.481%
Day's High: $12.5399 Week Perf: 6.07 %
Day's Low: $ 12.06 30 Day Perf: 7.91 %
Volume (M): 7 52 Wk High: $ 14.00
Volume (M$): $ 88 52 Wk Avg: $10.16
Open: $12.40 52 Wk Low: $6.07



 Market Capitalization (Millions $) 81
 Shares Outstanding (Millions) 7
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -197
 Cash Flow (TTM) (Millions $) -31
 Capital Exp. (TTM) (Millions $) 34

Instil Bio Inc
Instil Bio Inc is a biotechnology company that focuses on developing innovative cell and gene therapies for the treatment of cancer. The company is committed to utilizing cutting-edge technologies to engineer and modify immune cells to enhance their ability to recognize and destroy cancer cells. Instil Bio aims to transform the treatment landscape for cancer patients by offering personalized and effective therapies that harness the power of the immune system.


   Company Address: 3963 Maple Avenue, Suite 350 Dallas 75219 TX
   Company Phone Number: 499-3350   Stock Exchange / Ticker: NASDAQ TIL
   TIL is expected to report next financial results on March 30, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Management Announcement

Instil Bio: Overcoming Financial Challenges and Paving the Way for Cancer Therapies

Published Tue, Jan 16 2024 1:01 PM UTC


In exciting news in the field of biopharmaceuticals, Instil Bio, Inc. recently released a strategic update, outlining their path forward in developing revolutionary tumor infiltrating lymphocyte (TIL) therapies for patients battling cancer. The company, listed on NASDAQ as TIL, has been dedicated to finding innovative solutions for cancer treatment, but has faced signif...

Instil Bio Inc

Instil Bio Inc Shocks Investors with Operating Shortfall in Q3 2023


Date: November 14, 2023
Following the big players in the Biotechnology & Pharmaceuticals industry, some overlooked entities are reporting their financial numbers for the third quarter of 2023. Two such companies, TIL and Instil Bio Inc, have recently released their Q3 financial results, which reflect varying degrees of success and challenges within their respective operations.
TIL, a company focused on developing tumor infiltrating lymphocyte therapies for cancer treatment, reported an operating shortfall of $-66.716 million for Q3 2023. This decrease in performance is likely to raise concerns among investors who were eagerly hoping for improvements in TIL's business model during this period. TIL is expected to attract additional investments to support growth and strategy enhancements.

Instil Bio Inc

Instil Bio Inc Shatters Expectations with Remarkable Second Quarter Turnaround, Slashing Operating Deficit by Nearly 65% in 2023

The Biotechnology & Pharmaceuticals industry has always been a captivating field to study, with countless breakthroughs and advancements constantly reshaping the landscape. As consultants analyze the second quarter performance of 2023, there is an air of anticipation surrounding the financial results of one particular company, Instil Bio Inc.
In the April to June 30 reporting season of 2023, Instil Bio Inc surprised industry experts by managing to reduce its operating deficit to $-20.987 million. This is a significant improvement compared to the same time-frame a year prior, where the company recorded a much higher operating deficit of $-58.724 million. The ability to operate more economically showcases the company's growth and highlights its potential for future success.

Instil Bio Inc

Instil Bio Inc Faces Financial Challenges and Warns Investors to Proceed with Caution

Investing in the stock market is always a game of risk and reward. While some investments yield excellent profits, some can be outright disastrous. Thus, it is essential to thoroughly assess a company's financials before making an investment decision.
Instil Bio Inc, the emerging growth company in the Property & Casualty Insurance industry, has recorded an alarming cumulative net loss of $-226 million, resulting in a negative Return on Equity (ROE) of -58.59% for the 12 months ending in Q1 2023. Moreover, 50 other companies in the same industry recorded a higher ROE than Instil Bio Inc. With such a dismal financial performance, investors must exercise caution before investing in the company.
Although there has been a slight improvement in Instil Bio Inc's overall ranking, moving from 3538 to 2381, the first quarter results of 2023 have raised concerns. Industry experts are closely scrutinizing the operating deficit of $-58.446 million, which has worsened from $-54.286 million in Q1 2022. It is also worrying that the company has not reported any revenue for the quarter that ended in March 2023. Investors must be cautious and keep a watchful eye on the situation, as operating deficits and zero revenue generate massive risk for the company's stability and future potential.






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com